Therapeutic Asset Ratings

6,305 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Atezolizumab Malignant Mesothelioma	Cancer Research UK	P1/2	CC (45)
Atezolizumab Childhood Malignant Neoplasm	St. Jude Children's Research Hospital	P1/2	CC (45)
Atezolizumab Gastric Neoplasm	Cancer Research UK	P1/2	CC (45)
Atezolizumab Uterine Cervix Neoplasm	Cancer Research UK	P1/2	CC (45)
Aurora A Kinase Inhibitor Ly3295668 Lung Cancer	M.D. Anderson Cancer Center	P1/2	CC (45)
Autologous Bcma/Cd19 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Cd19 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Cd38 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Cd38 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Gprc5D Dual-Target Car-T T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Bcma/Gprc5D Dual-Target Car-T T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd20 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd20 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd22 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd19/Cd22 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cd123 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cd123 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cll1 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd33/Cll1 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd5/Cd7 Dual-Target Car-T Module T-Cell Acute Lymphoblastic Leukemia	Beijing Biotech	P1/2	CC (45)
Autologous Cd5/Cd7 Dual-Target Car-T Module T-Lymphoblastic Lymphoma	Beijing Biotech	P1/2	CC (45)
Autologous Cd7 Car T-Cell Acute Lymphoblastic Leukemia	Beijing GoBroad Hospital	P1/2	CC (45)
Autologous Cd7 Car T-Cell T-Cell Acute Lymphoblastic Leukemia	Beijing GoBroad Hospital	P1/2	CC (45)
Autologous Hucd19 Car T Cells B-Cell Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	P1/2	CC (45)
Autologous Human Cd34+ Hematopoietic Stem/Precursor Cells (Hspcs), Obtained From Peripheral Blood By Leukapheresis From Plerixaformobilized Sickle Cell Disease (Scd) Patients Or Granulocyte Colony Stimulating Factor (G-Csf) And Plerixafor-Mobilized Transfusion Dependent Betathalassemia (Tdt) Patients, Genetically Modified Ex Vivo By Crispr/Cas12A (Clustered Regularly Interspaced Palindromic Repeats/Modified Acidaminococcus Sp. Cas12A) Endonuclease Complexed With A Guide Rna (Grna) That Targets The Ccaat-Box Region Of Both Gamma Globin Gene (Hbg1 And Hgb2) Promoters On Chromosome 11, Creating Indels That Disrupt Repressor Binding And Increase Gamma Globin Expression. The Editing Components Are Introduced Into The Target Cell Population As A Ribonucleoprotein Complex By Electroporation. The Cell Suspension Is Enriched For Cd34+ Cells Using Magnetic Bead Separation. Following Electroporation, The Cells Are Cultured In Media Containing Thrombopoietin, Fms-Related Tyrosine Kinase 3 Ligand (Flt3L), And Stem Cell Factor (Scf). The Substance Consists Of Cells With ?70% Cd34/Cd45+ Purity And ?70% On-Target Editing. Hemoglobinopathy	Editas Medicine, Inc.	P1/2	CC (45)

Showing 2951 to 2975 of 6,305 assets

PreviousPage 119 of 253Next